Gastrointestinal stromal tumor: a review of current and emerging therapies
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Gastrointestinal stromal tumor: a review of current and emerging therapies
Authors
Keywords
-
Journal
CANCER AND METASTASIS REVIEWS
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-04-20
DOI
10.1007/s10555-021-09961-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Durable tumor regression in highly refractory metastatic KIT/PDGFRA wild-type GIST following treatment with nivolumab
- (2020) Brett A. Schroeder et al. OncoImmunology
- Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial
- (2020) Michael C Heinrich et al. LANCET ONCOLOGY
- Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants
- (2019) Bryan D. Smith et al. CANCER CELL
- Real-World Evidence of Patient Outcome Following Treatment of Advanced Gastrointestinal Stromal Tumor (GIST) with Imatinib, Sunitinib, and Sorafenib in Publicly Funded Health Care in Poland
- (2019) Melania Brzozowska et al. MEDICAL SCIENCE MONITOR
- A Phase I Study of Binimetinib (MEK162) Combined with Pexidartinib (PLX3397) in Patients with Advanced Gastrointestinal Stromal Tumor
- (2019) Evan Rosenbaum et al. ONCOLOGIST
- LBA87INVICTUS: A phase III, interventional, double-blind, placebo-controlled study to assess the safety and efficacy of ripretinib as ≥ 4th-line therapy in patients with advanced gastrointestinal stromal tumors (GIST) who have received treatment with prior anticancer therapies (NCT03353753)
- (2019) M von Mehren et al. ANNALS OF ONCOLOGY
- Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications
- (2017) Zoltan Szucs et al. Future Oncology
- The analysis of the long-term outcomes of sorafenib therapy in routine practice in imatinib and sunitinib resistant gastrointestinal stromal tumors (GIST)*
- (2017) Piotr Rutkowski et al. Wspolczesna Onkologia-Contemporary Oncology
- A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17
- (2017) Chun-Nan Yeh et al. Oncotarget
- Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib
- (2017) Heikki Joensuu et al. JAMA Oncology
- Combination of PKC412 and sirolimus in a metastatic patient with PDGFRA-D842V gastrointestinal stromal tumor (GIST)
- (2017) E. Palassini et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity of sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): A phase II trial of the University of Chicago Phase II Consortium
- (2017) L. Wiebe et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter, single-arm, two-stage phase II trial of everolimus (RAD001) with imatinib in imatinib-resistant patients (pts) with advanced GIST.
- (2017) P. Hohenberger et al. JOURNAL OF CLINICAL ONCOLOGY
- Final results of a University of Chicago phase II consortium trial of sorafenib (SOR) in patients (pts) with imatinib (IM)- and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST).
- (2017) N. P. Campbell et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy
- (2016) E. Ben-Ami et al. ANNALS OF ONCOLOGY
- Definition and clinical significance of tumour rupture in gastrointestinal stromal tumours of the small intestine
- (2016) T. Hølmebakk et al. BRITISH JOURNAL OF SURGERY
- Diagnostic and treatment strategy for small gastrointestinal stromal tumors
- (2016) Toshirou Nishida et al. CANCER
- Microscopic gastrointestinal stromal tumours: a clinical and molecular study of 13 cases
- (2016) William Anderson et al. HISTOPATHOLOGY
- Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial
- (2016) Heikki Joensuu et al. JOURNAL OF CLINICAL ONCOLOGY
- Pazopanib for both GIST and soft-tissue sarcoma
- (2016) Toshirou Nishida et al. LANCET ONCOLOGY
- Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial
- (2016) Olivier Mir et al. LANCET ONCOLOGY
- Cabozantinib Is Active against Human Gastrointestinal Stromal Tumor Xenografts Carrying Different KIT Mutations
- (2016) Yemarshet K. Gebreyohannes et al. MOLECULAR CANCER THERAPEUTICS
- Molecular Subtypes ofKIT/PDGFRAWild-Type Gastrointestinal Stromal Tumors
- (2016) Sosipatros A. Boikos et al. JAMA Oncology
- Are Rogerofenib and Nilotinib Effective for Advanced Gastrointestinal Stromal Tumor (GIST) Patients who have Already been Given Main Treatments?
- (2015) Ersin Ozaslan et al. Asian Pacific Journal of Cancer Prevention
- Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas
- (2015) Paolo G. Casali et al. JOURNAL OF CLINICAL ONCOLOGY
- Gastrointestinal stromal tumors (GISTs) at uncommon locations: A large population based analysis
- (2015) Moshim Kukar et al. JOURNAL OF SURGICAL ONCOLOGY
- Nilotinib, imatinib, and GIST therapy
- (2015) Xavier Garcia del Muro LANCET ONCOLOGY
- Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial
- (2015) Jean-Yves Blay et al. LANCET ONCOLOGY
- Combined Inhibition of MAP Kinase and KIT Signaling Synergistically Destabilizes ETV1 and Suppresses GIST Tumor Growth
- (2015) L. Ran et al. Cancer Discovery
- Epidemiology of Gastrointestinal Stromal Tumors in the Era of Histology Codes: Results of a Population-Based Study
- (2014) G. L. Ma et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Tumor Genotype Is an Independent Prognostic Factor in Primary Gastrointestinal Stromal Tumors of Gastric Origin: A European Multicenter Analysis Based on ConticaGIST
- (2014) A. Wozniak et al. CLINICAL CANCER RESEARCH
- Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients
- (2014) A. P. Garner et al. CLINICAL CANCER RESEARCH
- Aberrant DNA hypermethylation of SDHC: a novel mechanism of tumor development in Carney triad
- (2014) Florian Haller et al. ENDOCRINE-RELATED CANCER
- Pathologic and Molecular Features Correlate With Long-Term Outcome After Adjuvant Therapy of Resected Primary GI Stromal Tumor: The ACOSOG Z9001 Trial
- (2014) Christopher L. Corless et al. JOURNAL OF CLINICAL ONCOLOGY
- Thyroid Hormone Inactivation in Gastrointestinal Stromal Tumors
- (2014) Michelle A. Maynard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Quadruplewild-type (WT) GIST: defining the subset of GIST that lacks abnormalities of KIT, PDGFRA, SDH, or RAS signaling pathways
- (2014) Maria A. Pantaleo et al. Cancer Medicine
- A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib
- (2013) K. N. Ganjoo et al. ANNALS OF ONCOLOGY
- Long-term Results of Adjuvant Imatinib Mesylate in Localized, High-Risk, Primary Gastrointestinal Stromal Tumor
- (2013) Ronald P. DeMatteo et al. ANNALS OF SURGERY
- Role of rapid sequence whole-body MRI screening in SDH-associated hereditary paraganglioma families
- (2013) Kory W. Jasperson et al. Familial Cancer
- Succinate dehydrogenase deficiency in pediatric and adult gastrointestinal stromal tumors
- (2013) Martin G. Belinsky Frontiers in Oncology
- Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib
- (2012) P. Reichardt et al. ANNALS OF ONCOLOGY
- Crenolanib Inhibits the Drug-Resistant PDGFRA D842V Mutation Associated with Imatinib-Resistant Gastrointestinal Stromal Tumors
- (2012) M. C. Heinrich et al. CLINICAL CANCER RESEARCH
- Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group
- (2012) S. H. Park et al. INVESTIGATIONAL NEW DRUGS
- One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor
- (2012) Heikki Joensuu et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Efficacy and Safety of Regorafenib in Patients With Metastatic and/or Unresectable GI Stromal Tumor After Failure of Imatinib and Sunitinib: A Multicenter Phase II Trial
- (2012) Suzanne George et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) George D Demetri et al. LANCET
- Succinate Dehydrogenase-Deficient GISTs
- (2011) Markku Miettinen et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumours (GIST): Polish Clinical GIST Registry experience
- (2011) A. Wozniak et al. ANNALS OF ONCOLOGY
- Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial
- (2011) Aurore Blesius et al. BMC CANCER
- Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor
- (2011) Akira Sawaki et al. CANCER
- Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib
- (2011) C. Cauchi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Spectrum of KIT/PDGFRA/BRAF mutations and Phosphatidylinositol-3-Kinase pathway gene alterations in gastrointestinal stromal tumors (GIST)
- (2011) Marc Daniels et al. CANCER LETTERS
- Yield and Performance Characteristics of Endoscopic Ultrasound-Guided Fine Needle Aspiration for Diagnosing Upper GI Tract Stromal Tumors
- (2011) Rabindra R. Watson et al. DIGESTIVE DISEASES AND SCIENCES
- Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts
- (2011) Heikki Joensuu et al. LANCET ONCOLOGY
- DOG1 and PKC-θ are useful in the diagnosis of KIT-negative gastrointestinal stromal tumors
- (2011) Gu-Hyun Kang et al. MODERN PATHOLOGY
- Immunohistochemistry for SDHB Divides Gastrointestinal Stromal Tumors (GISTs) into 2 Distinct Types
- (2010) Anthony J. Gill et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors
- (2010) P. Schoffski et al. ANNALS OF ONCOLOGY
- Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib
- (2010) Paul W. Manley et al. BIOORGANIC & MEDICINAL CHEMISTRY
- DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours
- (2010) Marco Novelli et al. HISTOPATHOLOGY
- SDHB immunohistochemistry: a useful tool in the diagnosis of Carney–Stratakis and Carney triad gastrointestinal stromal tumors
- (2010) José Gaal et al. MODERN PATHOLOGY
- ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours
- (2010) Ping Chi et al. NATURE
- DOG1 Antibody in the Differential Diagnosis of Gastrointestinal Stromal Tumors
- (2009) Markku Miettinen et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- A Phase I Study of Single-Agent Nilotinib or in Combination with Imatinib in Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors
- (2009) G. D. Demetri et al. CLINICAL CANCER RESEARCH
- Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers
- (2009) J.C. Soria et al. EUROPEAN JOURNAL OF CANCER
- Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure
- (2009) S. George et al. EUROPEAN JOURNAL OF CANCER
- Pediatric Gastrointestinal Stromal Tumors
- (2009) Alberto S. Pappo et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- The triad of paragangliomas, gastric stromal tumours and pulmonary chondromas (Carney triad), and the dyad of paragangliomas and gastric stromal sarcomas (Carney-Stratakis syndrome): molecular genetics and clinical implications
- (2009) C. A. Stratakis et al. JOURNAL OF INTERNAL MEDICINE
- Sorafenib induces growth suppression in mouse models of gastrointestinal stromal tumor
- (2009) H. Huynh et al. MOLECULAR CANCER THERAPEUTICS
- A guide for the diagnosis and management of gastrointestinal stromal cell tumors
- (2009) Paul S. Sepe et al. Nature Reviews Gastroenterology & Hepatology
- Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT
- (2009) Patrice Dubreuil et al. PLoS One
- A Randomized, Phase II Study of Preoperative plus Postoperative Imatinib in GIST: Evidence of Rapid Radiographic Response and Temporal Induction of Tumor Cell Apoptosis
- (2008) John C. McAuliffe et al. ANNALS OF SURGICAL ONCOLOGY
- Therapeutic Consequences from Molecular Biology for Gastrointestinal Stromal Tumor Patients Affected by Neurofibromatosis Type 1
- (2008) C. Mussi et al. CLINICAL CANCER RESEARCH
- Molecular Characterization of Pediatric Gastrointestinal Stromal Tumors
- (2008) N. P. Agaram et al. CLINICAL CANCER RESEARCH
- Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST)
- (2008) M. Fiore et al. EJSO
- Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors
- (2008) Narasimhan P. Agaram et al. GENES CHROMOSOMES & CANCER
- Risk stratification of patients diagnosed with gastrointestinal stromal tumor
- (2008) Heikki Joensuu HUMAN PATHOLOGY
- Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group
- (2008) Michael C. Heinrich et al. JOURNAL OF CLINICAL ONCOLOGY
- Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor
- (2008) Michael C. Heinrich et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033
- (2008) Charles D. Blanke et al. JOURNAL OF CLINICAL ONCOLOGY
- A systematic review on the clinical diagnosis of gastrointestinal stromal tumors
- (2008) Marco Scarpa et al. JOURNAL OF SURGICAL ONCOLOGY
- Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665
- (2008) Burton L. Eisenberg et al. JOURNAL OF SURGICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started